公开(公告)号：US20230227540A1

公开(公告)日：2023-07-20

申请号：US16475853

申请日：2018-01-05

Applicant: ABL Bio Inc.

Inventor： Jinhyung AHN ,  Sungwon AN ,  Dongin KIM ,  Eunsil SUNG ,  Jaehyun EOM ,  Sang Hoon LEE ,  Seung-Jae LEE ,  Tae Kyung KIM ,  Min Sun CHOI ,  Weonkyoo YOU ,  Jaeho JUNG ,  Juhee KIM ,  Jinwon JUNG ,  Yeunju KIM ,  Yonggyu SON ,  Byungje SUNG

IPC: C07K16/18 ,  A61P25/14 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61P25/14 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/565

Abstract: The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

公开(公告)号：US20220056136A1

公开(公告)日：2022-02-24

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA CO., LTD

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Hyejin CHUNG ,  Eunsil SUNG ,  Jiseon YOO ,  Minji PARK ,  Yong-Gyu SON ,  Hyoju CHOI ,  Eunjung KIM ,  Jaeho JUNG ,  Weon-Kyoo YOU ,  Sang Hoon LEE ,  Lei FANG ,  Wenqing JIANG

IPC: C07K16/28 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US20240101687A1

公开(公告)日：2024-03-28

申请号：US18480071

申请日：2023-10-03

Applicant: ABL Bio Inc.

Inventor： Jinhyung AHN ,  Sungwon AN ,  Dongin KIM ,  Eunsil SUNG ,  Jaehyun EOM ,  Sang Hoon Lee ,  Weonkyoo YOU ,  Juhee KIM ,  Kyungjin PARK ,  Hyejin CHUNG ,  Jinwon JUNG ,  Bora LEE ,  Byungje SUNG ,  Yeunju KIM ,  Yong-Gyu SON ,  Seawon AHN ,  Daehae SONG ,  Jiseon YOO ,  Youngdon PAK ,  Donghoon YEOM ,  Yoseob LEE ,  Jaeho JUNG

IPC: C07K16/28 ,  A61K47/68 ,  C07K16/18

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

公开(公告)号：US20220363763A1

公开(公告)日：2022-11-17

申请号：US17269784

申请日：2019-08-21

Applicant: ABL BIO INC.

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Uijung JUNG ,  YoungKwang KIM ,  Yeun Ju KIM ,  Youngdon PAK ,  Sang Hoon LEE ,  Weon-Kyoo YOU ,  Jaeho JUNG ,  Lei FANG ,  Wenqing JIANG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.